Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Public Information Strategy Is “Dangerous” And “Imprecise” – AEI Fellow

Executive Summary

FDA's increasing reliance on public health advisories to convey drug safety information is "dangerous" because the messages do not target the appropriate audience, American Enterprise Institute Resident Fellow Scott Gottlieb said

You may also be interested in...



Antipsychotic Risk Examined In NEJM; Did FDA Judge Atypicals Unfairly?

Conventional antipsychotic medications should not be prescribed as replacements for atypical products despite an FDA public health advisory about the newer agents because conventional medications appear to have higher mortality in elderly patients, an article in the Dec. 1 New England Journal of Medicine concludes

Antipsychotic Risk Examined In NEJM; Did FDA Judge Atypicals Unfairly?

Conventional antipsychotic medications should not be prescribed as replacements for atypical products despite an FDA public health advisory about the newer agents because conventional medications appear to have higher mortality in elderly patients, an article in the Dec. 1 New England Journal of Medicine concludes

FDA Rx Safety Website Will Include Drugs With Emerging Off-Label Issues

FDA's "Drug Watch" website will include safety information on drugs that have emerging safety signals for off-label uses

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel